secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2022-05-23T23:59:59+00:00
Accession:  0001193125-22-157512
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

MindMed appoints Schond Greenway as CFO, effective May 23, 2022
---------------------------------------------------------------

- Schond Greenway named CFO effective May 23, 2022; previously CFO at Avalo Therapeutics.
- Base salary of $400,000; eligible for discretionary annual cash bonus with 40% target.
- Received option for 1,650,000 shares (4-yr vest) and RSU for 1,270,000 shares (4-yr vest).
- Greenway brings experience from Avalo, Mesoblast, Halozyme, and investment banks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000119312522157512/0001193125-22-157512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000119312522157512/d320568d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-157512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer